Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2006 2
2008 1
2009 2
2010 5
2011 10
2012 9
2013 5
2014 4
2015 6
2016 1
2017 2
2018 1
2019 6
2020 3
2021 10
2022 9
2023 9
2024 12

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

91 results

Results by year

Filters applied: . Clear all
Page 1
The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4-Related Disease.
Wallace ZS, Naden RP, Chari S, Choi H, Della-Torre E, Dicaire JF, Hart PA, Inoue D, Kawano M, Khosroshahi A, Kubota K, Lanzillotta M, Okazaki K, Perugino CA, Sharma A, Saeki T, Sekiguchi H, Schleinitz N, Stone JR, Takahashi N, Umehara H, Webster G, Zen Y, Stone JH; American College of Rheumatology/European League Against Rheumatism IgG4-Related Disease Classification Criteria Working Group. Wallace ZS, et al. Among authors: khosroshahi a. Arthritis Rheumatol. 2020 Jan;72(1):7-19. doi: 10.1002/art.41120. Epub 2019 Dec 2. Arthritis Rheumatol. 2020. PMID: 31793250
Consensus statement on the pathology of IgG4-related disease.
Deshpande V, Zen Y, Chan JK, Yi EE, Sato Y, Yoshino T, Klöppel G, Heathcote JG, Khosroshahi A, Ferry JA, Aalberse RC, Bloch DB, Brugge WR, Bateman AC, Carruthers MN, Chari ST, Cheuk W, Cornell LD, Fernandez-Del Castillo C, Forcione DG, Hamilos DL, Kamisawa T, Kasashima S, Kawa S, Kawano M, Lauwers GY, Masaki Y, Nakanuma Y, Notohara K, Okazaki K, Ryu JK, Saeki T, Sahani DV, Smyrk TC, Stone JR, Takahira M, Webster GJ, Yamamoto M, Zamboni G, Umehara H, Stone JH. Deshpande V, et al. Among authors: khosroshahi a. Mod Pathol. 2012 Sep;25(9):1181-92. doi: 10.1038/modpathol.2012.72. Epub 2012 May 18. Mod Pathol. 2012. PMID: 22596100 Free article. Review.
Rituximab for IgG4-related disease: a prospective, open-label trial.
Carruthers MN, Topazian MD, Khosroshahi A, Witzig TE, Wallace ZS, Hart PA, Deshpande V, Smyrk TC, Chari S, Stone JH. Carruthers MN, et al. Among authors: khosroshahi a. Ann Rheum Dis. 2015 Jun;74(6):1171-7. doi: 10.1136/annrheumdis-2014-206605. Epub 2015 Feb 9. Ann Rheum Dis. 2015. PMID: 25667206
The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease.
Wallace ZS, Naden RP, Chari S, Choi HK, Della-Torre E, Dicaire JF, Hart PA, Inoue D, Kawano M, Khosroshahi A, Lanzillotta M, Okazaki K, Perugino CA, Sharma A, Saeki T, Schleinitz N, Takahashi N, Umehara H, Zen Y, Stone JH; Members of the ACR/EULAR IgG4-RD Classification Criteria Working Group. Wallace ZS, et al. Among authors: khosroshahi a. Ann Rheum Dis. 2020 Jan;79(1):77-87. doi: 10.1136/annrheumdis-2019-216561. Epub 2019 Dec 3. Ann Rheum Dis. 2020. PMID: 31796497 Review.
International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease.
Khosroshahi A, Wallace ZS, Crowe JL, Akamizu T, Azumi A, Carruthers MN, Chari ST, Della-Torre E, Frulloni L, Goto H, Hart PA, Kamisawa T, Kawa S, Kawano M, Kim MH, Kodama Y, Kubota K, Lerch MM, Löhr M, Masaki Y, Matsui S, Mimori T, Nakamura S, Nakazawa T, Ohara H, Okazaki K, Ryu JH, Saeki T, Schleinitz N, Shimatsu A, Shimosegawa T, Takahashi H, Takahira M, Tanaka A, Topazian M, Umehara H, Webster GJ, Witzig TE, Yamamoto M, Zhang W, Chiba T, Stone JH; Second International Symposium on IgG4-Related Disease. Khosroshahi A, et al. Arthritis Rheumatol. 2015 Jul;67(7):1688-99. doi: 10.1002/art.39132. Arthritis Rheumatol. 2015. PMID: 25809420 Review. No abstract available.
Obexelimab in Systemic Lupus Erythematosus With Exploration of Response Based on Gene Pathway Co-Expression Patterns: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial.
Merrill JT, Guthridge J, Smith M, June J, Koumpouras F, Machua W, Askanase A, Khosroshahi A, Sheikh SZ, Rathi G, Burington B, Foster P, Matijevic M, Arora S, Wang X, Gao M, Wax S, James JA, Zack DJ. Merrill JT, et al. Among authors: khosroshahi a. Arthritis Rheumatol. 2023 Dec;75(12):2185-2194. doi: 10.1002/art.42652. Arthritis Rheumatol. 2023. PMID: 37459248 Clinical Trial.
Development of an IgG4-RD Responder Index.
Carruthers MN, Stone JH, Deshpande V, Khosroshahi A. Carruthers MN, et al. Among authors: khosroshahi a. Int J Rheumatol. 2012;2012:259408. doi: 10.1155/2012/259408. Epub 2012 Apr 24. Int J Rheumatol. 2012. PMID: 22611406 Free PMC article.
Inebilizumab for Treatment of IgG4-Related Disease.
Stone JH, Khosroshahi A, Zhang W, Della Torre E, Okazaki K, Tanaka Y, Löhr JM, Schleinitz N, Dong L, Umehara H, Lanzillotta M, Wallace ZS, Ebbo M, Webster GJ, Martinez Valle F, Nayar MK, Perugino CA, Rebours V, Dong X, Wu Y, Li Q, Rampal N, Cimbora D, Culver EL; MITIGATE Trial Investigators. Stone JH, et al. Among authors: khosroshahi a. N Engl J Med. 2024 Nov 14. doi: 10.1056/NEJMoa2409712. Online ahead of print. N Engl J Med. 2024. PMID: 39541094
91 results